Gilead Sciences Is Now More Attractive After Showing Superior Results Of Its Newest HIV Drug

Gilead's stock is extremely undervalued, and it still has high growth prospects due to new revolutionary drugs in its pipeline and a possible big acquisition. The average target price of the top analysts is at $84.17, an upside of 24.6%.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.